~~<i id='060C5D0B9F'><strike id='060C5D0B9F'><tt id='060C5D0B9F'><pre id='060C5D0B9F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：entertainment 2025-09-30 17:45:38 - browse：7851

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： To avoid data mishandling cases, universities eye AI and other tools

hotspot

knowledge

entertainment

YASSERAL-ZAYYAT/AFPviaGettyImagesPublichealthmessageshavetoldusfordecadesthatifyousmoke,youshouldqui

WSS

BioAge raises $170M for combination therapy with Zepbound

Doctors' information doesn't help them choose wisely when sick

3 questions for the future of Biden's cancer moonshot

Bristol 'take

Readout LOUD podcast: How biotech is using artificial intelligence

Histogen: Failed biotech offers rare public look inside

entertainment

hotspot

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The future of health care in the House

Medical leaders decry Supreme Court decision on affirmative action

Senators start work on Medicare physician payment reform

Jerome Adams on the need for new antivirals for Covid

Industry veterans launch new biotech VC with $310M

Trump demands the U.S. pay no more for drugs than other countries … again

Was Amgen transparent enough on FDA's concern on cancer drug?

Medical leaders decry Supreme Court decision on affirmative action

Analysis of telehealth claims data suggest service duplication

hotspot

Gilead might be held responsible for not developing a drug

Senators start work on Medicare physician payment reform

Key House Republican on health care plans exit from Congress

Bristol 'take

The Readout: Gilead, Bernie Sanders, and other pharma news

FDA authorizes Novavax’s updated Covid

hotspot

hotspot

knowledge

entertainment